Ring Therapeutics has harnessed the commensal virome with the creation of a novel class of gene therapy vectors, known as Anellovectors. In this work, we present considerations for downstream purification of this novel class of gene therapy vectors ranging from harvest, chromatography, and TFF unit operations.

Downstream process development for the next generation of gene therapy vectors: Anellovectors

ACS Spring 2022

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.